Radiofrequency Ablation News and Research RSS Feed - Radiofrequency Ablation News and Research

Thermal ablation is heating tumors so hot that the tumor cells die. It has been studied in many forms, including microwave, laser, high-intensity focused ultrasound, and cryotherapy (freezing below -20 C). Radiofrequency thermal ablation or radiofrequency ablation (RFA) has emerged as the most commonly used technology for thermal ablation in the bone, liver, kidney, lung, heart, breast, lymph nodes, nerve ganglia, and soft tissue.
Arrhythmias worth treating in PAH patients

Arrhythmias worth treating in PAH patients

Supraventricular arrhythmias are common in patients with pulmonary arterial hypertension but can be successfully managed with standard treatments, a study shows. [More]
Korean MFDS approves InSightec's Exablate Neuro system to treat movement, pain and behavioral disorders

Korean MFDS approves InSightec's Exablate Neuro system to treat movement, pain and behavioral disorders

Elbit Imaging Ltd. announced today that it was informed by InSightec Ltd., that the Korean Ministry of Food and Drug Safety has approved its Exablate Neuro system to treat movement, pain and behavioral disorders. [More]
Minimally invasive implant procedure effective for patients with sacroiliac joint dysfunction

Minimally invasive implant procedure effective for patients with sacroiliac joint dysfunction

A minimally invasive implant procedure is highly effective in reducing pain and disability for patients with sacroiliac joint (SIJ) dysfunction, reports a clinical trial in the November issue of Neurosurgery, official journal of the Congress of Neurological Surgeons, published by Wolters Kluwer. [More]
Study looks at survival benefits of surgical resection for melanoma patients with abdominal metastases

Study looks at survival benefits of surgical resection for melanoma patients with abdominal metastases

Patients with metastatic melanoma who undergo surgery to remove lesions that have spread into the abdomen live more than twice as long as those treated with drug therapy alone, according to novel new research by a North Shore-LIJ Health System cancer surgeon. [More]
EORTC and ESSO project provides opportunity to do prospective study on liver metastasis surgery

EORTC and ESSO project provides opportunity to do prospective study on liver metastasis surgery

Is it possible to cure patients with unresectable colorectal liver metastases? Are complex surgeries safe for patients with extensive metastatic disease? How can we monitor and improve the quality of these surgical strategies? How can we improve surgical care for patients through research? [More]
First-line catheter ablation treatment superior to drug therapy for suppressing AF

First-line catheter ablation treatment superior to drug therapy for suppressing AF

First-line treatment with catheter ablation is superior to drug therapy for reducing atrial fibrillation, according to five year results from the MANTRA-PAF trial presented for the first time at ESC Congress today. [More]
Study finds no significant impact of ATP on reducing late recurrence of AF

Study finds no significant impact of ATP on reducing late recurrence of AF

Late recurrence of atrial fibrillation (AF) is not reduced in patients whose pulmonary vein isolation (PVI) treatment incorporates the addition of adenosine triphosphate (ATP), according to results of the UNDER-ATP trial. [More]
Celsion reports updated results from HEAT Study of ThermoDox in patients with primary liver cancer

Celsion reports updated results from HEAT Study of ThermoDox in patients with primary liver cancer

Celsion Corporation, an oncology drug development company, today announced updated results from its retrospective analysis of the Company's 701-patient HEAT Study of ThermoDox, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin in combination with radiofrequency ablation (RFA) in primary liver cancer, also known as hepatocellular carcinoma (HCC). [More]
Children's National Health System first in U.S. to treat osteoid osteoma using MR-HIFU method

Children's National Health System first in U.S. to treat osteoid osteoma using MR-HIFU method

Doctors from the Sheikh Zayed Institute for Pediatric Surgical Innovation at Children's National Health System are the first in the United States to treat osteoid osteoma, a benign but painful bone tumor that commonly occurs in children and young adults, using an experimental magnetic resonance-guided high-intensity focused ultrasound (MR-HIFU) method. [More]
Study: Early improvements not sustained in patients treated with PRP injection for facet joint arthropathy

Study: Early improvements not sustained in patients treated with PRP injection for facet joint arthropathy

Early gains in pain relief, behavioral markers and function were not sustained in patients treated with platelet-rich plasma (PRP) injection for facet joint arthropathy, new research shows. Results were available at the 31st Annual Meeting of the American Academy of Pain Medicine. [More]
AAPM announces recipients of 2015 Pain Medicine Fellowship Excellence Award

AAPM announces recipients of 2015 Pain Medicine Fellowship Excellence Award

The American Academy of Pain Medicine is pleased to announce its 2015 Pain Medicine Fellowship Excellence Award Recipients in recognition of a Pain Medicine Fellowship Program that provides an exceptional learning experience to its fellows, preparing them to deliver the highest standard of care to patients with pain. [More]
Report supports potential of focused ultrasound to treat certain OCD patients

Report supports potential of focused ultrasound to treat certain OCD patients

A recently published report in the Journal of Molecular Psychiatry supports the potential of focused ultrasound to treat certain patients with obsessive-compulsive disorder (OCD). [More]
Guidelines for management of small renal masses questioned

Guidelines for management of small renal masses questioned

Partial nephrectomy and percutaneous ablation for small and localised renal masses produce similar rates of local tumour recurrence, report US researchers. [More]
Partial nephrectomy offers near equivalent lengths of cancer control compared to radical nephrectomy

Partial nephrectomy offers near equivalent lengths of cancer control compared to radical nephrectomy

Needle-guided tumor destruction procedures offer near equivalent lengths of local cancer control compared to surgery for patients with small kidney cancer tumors, according to the results of a large study published in the journal European Urology. [More]
Celsion announces financial results for second quarter ended 2014

Celsion announces financial results for second quarter ended 2014

Celsion Corporation, an oncology drug development company, today announced financial results for the second quarter ended June 30, 2014. [More]
Surgical treatment improves survival for metastatic melanoma patients whose disease is limited to the liver

Surgical treatment improves survival for metastatic melanoma patients whose disease is limited to the liver

Surgical resection markedly improves survival among metastatic melanoma patients whose disease is isolated to a few areas in the liver, according to new study findings published in the July issue of the Journal of the American College of Surgeons. [More]
First patient successfully treated for symptomatic uterine fibroids with Gynesonics' VizAblate System

First patient successfully treated for symptomatic uterine fibroids with Gynesonics' VizAblate System

Gynesonics, Inc., a women's healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, today announced the first treatment of a patient in Cologne, Germany, using the Company's newly-designed VizAblate System. [More]
Celsion acquires all assets of EGEN

Celsion acquires all assets of EGEN

Celsion Corporation, an oncology drug development company, today announced the completion of the acquisition by Celsion of substantially all of the assets of EGEN, Inc., a privately-held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases. [More]
Celsion signs definitive asset purchase agreement to acquire EGEN

Celsion signs definitive asset purchase agreement to acquire EGEN

Celsion Corporation (Celsion) (NASDAQ: CLSN), an oncology drug development company, and EGEN, Inc. (EGEN), a privately-held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases, today announced the signing of a definitive asset purchase agreement in which Celsion will acquire substantially all of the assets of EGEN, including its Phase Ib DNA-based immunotherapy product candidate EGEN-001 and its therapeutic platform technologies, TheraPlas™ for delivery of DNA and mRNA, TheraSilence™ for delivery of RNA, and RAST™ for Cell Enabled Expression and Secretion of RNA. [More]
Effects of radiofrequency ablation and complete endoscopic resection are equal in dysplastic Barrett's esophagus

Effects of radiofrequency ablation and complete endoscopic resection are equal in dysplastic Barrett's esophagus

According to a new systematic review article, radiofrequency ablation and complete endoscopic resection are equally effective in the short-term treatment of dysplastic Barrett's esophagus, but adverse event rates are higher with complete endoscopic resection. [More]
Advertisement
Advertisement